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Abstract
Background: It has been hypothesized that dexamethasone can inhibit persistent postoperative pain, but data on
humans is lacking and results from animal studies are conflicting. We explored the effect of 16 mg dexamethasone
IV administered preoperatively on persistent pain 1 year after lumbar discectomy.
Methods: This is a prospective 1-year follow-up on a single-centre, randomized, and blinded trial exploring the
analgesic effect of 16 mg IV dexamethasone or placebo after lumbar discectomy. One year follow-up was a written
questionnaire including back and leg pain (VAS 0–100 mm), Short Form 36 survey (SF-36), EuroQol 5D (EQ-5D),
OSWESTRY Low Back Pain Questionnaire, duration of sick leave, working capability, contentment with surgical result.
Results: Response rate was 71% (55 patients) in the dexamethasone group, 58% (44 patients) in the placebo
group. Leg pain (VAS) was significantly lower in the placebo group compared to the dexamethasone group: 17
(95% CI 10–26) vs 26 (95% CI 19–33) mm, respectively (mean difference 9 mm (95% CI −1 to 0), (P = 0.03). No
difference regarding back pain. The placebo group reported significantly more improvement of leg pain and were
significantly more satisfied with the surgical result. Patients in the dexamethasone group reported significantly
higher pain levels in EQ-5D- and Oswestry questionnaires. No difference in the SF-36 survey or daily analgesic
consumption.
Conclusions: We found significantly higher pain levels in the dexamethasone group compared to placebo 1 year
after lumbar disc surgery.
Trial registration: Clinicaltrials.gov (NCT01953978). Registered 26 Sep 2013.
Keywords: Dexamethasone, Glucocorticoids, Persistent postoperative pain, Preemptive medicine, Spine surgery
Background
An increasing number of studies have explored the role
of glucocorticoids as a potential adjuvant in analgesic
regimens for acute postoperative pain management [1, 2].
Reviews and metaanalyses’ indicate that dexamethasone in
doses of 0.1–0.2 mg/kg provides an opioid-sparing effect
and lower pain scores after surgery [1, 2]. Moreover, it is
speculated that perioperative administration of glucocorti-
coids may prevent persistent postoperative pain but
follow-up periods have been relatively short and
insufficient to detect possible long term beneficial or
harmful effects [1–4].
The mechanisms that influence the transition from
acute, adaptive postoperative pain to persistent, maladap-
tive pain are uncertain, but nerve injury and ongoing in-
flammation play important roles [5]. Peripheral- and
central sensitizations are fundamental mechanisms of the
development of pain chronicity in the postoperative
period. Proinflammatory cytokines secreted at or near the
site of a nerve injury are involved in the development and
maintenance of central sensitization and neuropathic pain
[6, 7]. Glucocorticoids suppress proinflammatory cyto-
kines and induce expression of anti-inflammatory cyto-
kines [7, 8]. By inhibiting the release of prostaglandins,
and production of proinflammatory cytokines, excitatory
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amino acids, and growth factors in animal models,
glucocorticoids prevent the development of neuro-
pathic pain [9, 10].
Persistent postsurgical pain is a serious and widely
unnoticed clinical problem, difficult to treat and often
permanent [5, 11, 12]. The level of acute postoperative
pain is associated with the risk of developing persistent
pain [13–15]. However, knowledge of the impact of ag-
gressive, early therapy for persistent, postoperative pain
is lacking [12, 16]. Therefore, we aimed to explore the
pre-emptive effect of 16 mg dexamethasone IV adminis-
tered preoperatively on persistent postoperative pain
1 year after lumbar disc surgery.
Methods
This is a prospective 1-year follow up trial on a single-
centre, prospective, randomized, and blinded trial ex-
ploring the analgesic effect of 16 mg dexamethasone IV
on acute postoperative pain after lumbar disc surgery as
the main outcome [17]. The trial was approved by the
Regional Research Ethics Committee and the Danish
Data Protection Agency and registered at clinicaltrials.-
gov (NCT01953978).
The trial was performed at Glostrup Hospital,
Copenhagen University Hospital, Glostrup, Denmark
during the period December 7, 2012 to December 7,
2014, and was monitored by the Copenhagen University
Hospital Good Clinical Practice Unit. The follow up
period was from December 1, 2013 to September 20,
2015. The study fulfilled the guidelines for Good Clinical
Practice and the Helsinki Declarations. The protocol, de-
sign and reporting of the study complied with the Stand-
ard Protocol Items, Recommendations for Interventional
Trials (SPIRIT) statement [18], and the Consolidated
Standards of Reporting Clinical Trials statement (CON-
SORT) [19]. The SF-36 version 1 (freeware) was used for
the 1-year follow-up. All patients gave written informed
consent before participating in the trial.
In- and exclusion criteria
One hundred-sixty patients undergoing one- or two-
level primary lumbar discectomy during general anaes-
thesia were approached for inclusion in the original trial
[17]. Inclusion criteria were age 18–85 years, American
Society of Anaesthesiologists (ASA) physical status clas-
sification of I to III, and body mass index between 18
and 40 kg/m2. Exclusion criteria were inability to co-
operate, inability to speak or understand Danish, previ-
ous spine surgery, pregnancy, allergy to drugs applied in
the trial, daily use of systemic steroids or strong opioids
(morphine, oxycodone, methadone, fentanyl, or ketobe-
midone), and alcohol or drug abuse (see also [17]).
Randomization and blinding
In the original trial, patients were randomly assigned to
one of two groups: Oral paracetamol + oral ibuprofen +
IV dexamethasone 16 mg; or oral paracetamol + oral
ibuprofen + IV placebo. Randomization was performed
by the pharmacy according to a computer-generated
block randomization list (each block containing 10 num-
bers), in a 1:1 ratio. Study medication was pre-packed by
the pharmacy in consecutively numbered boxes according
to the computer generated randomization list, containing
identical 1 ml ampules of either dexamethasone 4 mg/ml
(Dexamethasone®, GALEN pharma GmbH, Germany), or
isotonic sodium chloride 9 mg/ml. The intervention was
blinded to patients, investigators, surgeons, and clinical
personnel (for further information, please see [17]).
The randomization code was disclosed until a three
months follow-up period had ended, exclusion of pa-
tients was decided, and statistical handling of the data
was completed, but prior to the 1-year follow-up.
The primary outcome of the original trial was pain
during mobilization 2 to 24 h postoperatively calculated
as a ‘weighted average level’ area under the curve (AUC)
(in mm) [17].
Secondary outcomes included pain at rest (AUC, 2–
24 h), total morphine consumption 0–24 h postopera-
tively, and 3- and 12-months follow-up (for further
information, see [17]).
One-year follow-up
The 1-year follow-up was performed by a written ques-
tionnaire. The questionnaire was used with permission
from Centre for Rheumatology and Spine Diseases,
Glostrup University Hospital, Denmark, and the Danish
Spine Database. This questionnaire was developed to
construct a national database that systematically collects
data on patients undergoing spine surgery. The ques-
tionnaire consists of demographic data, back and leg
pain (VAS 0–100 mm), duration of sick leave, working
capability and contentment with the results of the oper-
ation. Further it contains the following questionnaires:
Short form 36 survey (SF-36), EuroQol 5D (EQ-5D) and
OSWESTRY Low Back Pain Questionnaire.
If patients had not returned the questionnaire after
three weeks, they received one written reminder.
Statistical methods
We randomized 160 subjects in the original study, and
data on acute pain were analysed in 77 and 76 patients in
the dexamethasone and placebo groups, respectively [17].
For the present data, we used SPSS version 22.0 for
Windows (SPSS, Chicago, Illinois) for statistical analysis.
Variables were tested for normal distribution with the
Kolmogorov-Smirnov test and visual inspection. Data
that followed normal distribution were compared using
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the independent samples t test. The Mann–Whitney U-
test was used for data that were not normally distrib-
uted. Categorical data were analyzed using the x2 test or
Fisher’s exact test if any cells had expected counts less
than five. Data are presented as mean (SD), mean (95%
confidence interval), median (lower and upper quartiles)
or frequencies (95% confidence interval), as appropriate.
A sensitivity analysis was performed for missing data on
the VAS pain scores with multiple, average, best case
and worst case imputation.
OSWESTRY Index Score is calculated using the fol-
lowing method: Questions are rated on a scale of 0–5
with zero recorded as no disability and five recorded as
maximum disability. The scores from all questions are
summed, and then multiplied by two to attain an index
(range 0–100). Zero is then no disability and 100 is max-
imum disability.
The SF-36 questionnaire is summarized as two sets of
scores: A profile of eight section scores, and two sum-
mary scores, one for the physical component (PCS) and
one for the mental component (MCS) summary scores.
Scores are recalculated to normal zero-to-100 scores for
the eight scales and all item scores are oriented so that
high scores correspond to better health. All scores are
calculated according to the formula described by
McDowell [20]. Using norm-based scoring (NBS) for the
summary scores, each scale is scored to have the same
mean (50) and standard deviation (10) as in the general
Swedish population, provided by SF-36 organization.
Anytime a scale score is below 50, health status is below
average relative to the general Swedish population.
The nature of the hypothesis testing was 2-tailed. P
values of less than 0.05 were considered statistically
significant. As we consider the results of this 1-year-
follow-up trial exploratory, outcomes were not statis-
tically corrected for mass significance. The primary
investigator carried out statistical analyses.
Results
All 153 patients included in the original data analysis, 77
and 76 subjects in the dexamethasone and placebo
groups, respectively, received a follow-up questionnaire
1 year postoperatively. In the dexamethasone group 55
patients (71%) replied, and in the placebo group 44 pa-
tients replied (58%), resulting in an overall response rate
of 65% (Fig. 1). Patient characteristics (age, height,
Fig. 1 CONSORT flowchart of trial
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weight, preoperative pain, postoperative pain 2–24 h and
morphine consumption 0–24 h) for responders and
non-responders were compared with no significant dif-
ferences between groups.
Spine unit questionnaire
For VAS back pain levels at one year postoperatively,
there was no significant difference between groups: 22
(95% CI 16–28) vs 20 (95% CI 14–28) mm in the dexa-
methasone and placebo groups, respectively (mean differ-
ence 2 mm (95% CI −1 to 0), P = 0.47 (Fig. 2)). Leg VAS
pain levels was significantly lower in the placebo group
compared to the dexamethasone group: 17 (95% CI 10–
26) vs 26 (95% CI 19–33) mm, respectively (mean differ-
ence 9 mm (95% CI −1 to 0), (P = 0.03) (Fig. 2).
Further, when asked how patients evaluated their leg
pain today compared to preoperatively, the placebo
group reported a significantly higher degree of improve-
ment of their leg pain, compared to the dexamethasone
group: 1 (0 – 5) vs 2 (0 – 5), respectively, (P = 0.04)
(Table 1). Table 2 summarizes multiple, average, best
case and worst case imputation for missing data on pain
scores.
A post hoc analysis of preoperative VAS pain scores
and VAS pain during the trial period (weighted average
AUC (wAUC) 2–24 h), showed that results from the
subgroup of patients that completed the 1-year follow-
up were similar to the results from the total study popu-
lation. Only pain during mobilization was significantly
different between groups: Dexamethasone compared to
placebo, 33 (22) vs 43 (18) mm (wAUC 2–24 h) with a
mean difference of 10 mm (95% CI 3 to 16), (P = 0.01) in
the original total study population and 32 (20) vs 41 (20)
mm with a mean difference of 11 mm (95% CI 2 to 18),
(P = 0.02) in the subgroup of one-year follow-up re-
sponders [17].
The relation between leg pain levels 3- and 12 months
postoperatively are summarized in scatter plots (Fig. 3).
The frequency of patients having leg pain (VAS) >
30 mm both 3- and 12 months postoperatively was 23%
and 8% in the dexamethasone group and placebo group,
respectively (P = 0.07).
Daily use of analgesics at 1 year postoperatively was
not different between groups, with 16% (95% CI 7–27)
(P = 0.84) having a daily use of analgesics in both groups
(Table 1). Preoperatively, the daily use of analgesics was,
64% (95% CI 51–74) in the dexamethasone group and
59% (95% CI 50–69) in the placebo group, including
only the patients that completed the 1-year follow up.
Working ability was not significantly different between
groups (Table 1). Satisfaction with the surgical result
was significantly lower in the dexamethasone group as
compared to the placebo group (P = 0.02) (see Table 1).
Short form 36 survey (SF-36)
The SF-36 section scores are summarized in Table 3.
Scores were generally lower in the dexamethasone group
indicating poorer health, especially regarding physical
health, although there were no significant differences be-
tween groups. The physical (PCS) component summary
score was mean 46 and 50 in the dexamethasone group
and placebo group, respectively, P = 0.69. The mental
(MCS) component summary score was mean 52 and 54
in the dexamethasone group and placebo group, respect-
ively, P = 0.49.
EuroQol 5D (EQ-5D)
Results from the EQ-5D questionnaire are summarized in
Fig. 3. There was a significant difference in severity of
Pain/Discomfort between groups, with 28/67/5% in the
dexamethasone group reporting no/moderate/severe pain,
respectively, and 50/45/5% in the placebo group reporting
no/moderate/severe pain, respectively, (P = 0.03) (Fig. 4).
There was no significant difference between groups in
self-reported health (VAS scale) with medians of 80
(4–100) vs 80 (14–100) mm in the dexamethasone
and placebo groups, respectively, (P = 0.26).
OSWESTRY low back pain questionnaire
Results from OSWESTRY Low Back Pain Questionnaire
are summarized as an Oswestry Index Score 0–100, with
0–20 being minimal disability and 81–100 being patients
who are bed-bound. There was no significant difference
between groups: Dexamethasone median 14 (0–60) vs
placebo median 8 (0–56), (P = 0.09), categorizing both
groups with minimal disability. However, in the question-
naire, there was a significant difference regarding pain
Fig. 2 Postoperative back- and leg pain (VAS). Leg pain 12 months
postoperatively was significantly less in the placebo group compared to
the dexamethasone group: 17 (95% CI 10–26) vs 26 (95% CI 19–33)
mm, respectively, with a mean difference of 9 mm (95% CI −1 to 0),
P= 0.033. There were no other significant differences between groups
Nielsen et al. BMC Anesthesiology  (2016) 16:112 Page 4 of 9
with more severe pain scores in the dexamethasone group:
Median 1 (0–5) vs placebo median 1 (0–3), (P = 0.01).
Discussion
In this prospective follow-up on a single-centre, prospect-
ive, randomized, blinded trial exploring the analgesic ef-
fect of 16 mg dexamethasone IV on acute postoperative
pain after lumbar disc surgery, we found significantly
higher chronic pain levels in the dexamethasone group at
one-year postoperatively. Leg pain was significantly higher
in the dexamethasone group compared to the placebo
group, measured on two different parameters, as in both
the EQ-5D and OSWESTRY surveys, questions on pain/
discomfort revealed higher scores in the dexamethasone
group.
Further, satisfaction with the surgical result was signifi-
cantly reduced in the dexamethasone group compared
to the placebo group.
Table 1 Follow up 12 months postoperatively
Dexamethasone Placebo P-value
Patient characteristics
Number of patients, n 55 44
Response rate, % 71 58
Time from operation to follow up, days 364 (12) 366 (11) 0.31
Height, cm 176 (8) 177 (10) 0.41
Weight, kg 79 (14) 83 (14) 0.21
Sex, f/m 27/28 15/29
Outcome
Back pain now compared to preoperatively 2 (1 – 3) 2 (1 – 2) 0.19
Leg pain now compared to preoperatively 2 (1 – 3) 1 (1 – 2) 0.04
VAS back pain, 0–100 mm 22 (16–28) 20 (14–28) 0.47
VAS leg pain, 0–100 mm 26 (19–33) 17 (10–26) 0.03
Uses analgesics 12 months postoperatively, % 0.84
Daily 16 (7 – 27) 16 (7 – 27)
As needed 31 (20 – 45) 36 (23 – 52)
Currently on sick leave because of back problem, % 13 (4 – 22) 5 (0 – 11) 0.17
Sickleave < 3 months postoperatively, % 79 (58 – 81) 84 (70 – 95) 0.21
Transferred to less demanding job postoperatively, % 15 (4 – 27) 19 (8 – 32) 0.59
Working % 79 (58 – 81) 84 (61 – 87) 0.89
Sports active, % 51 (38 – 64) 68 (48 – 77) 0.09
Walk distance more than 1000 m, % 80 (69 – 89) 91 (82 – 98) 0.21
Satisfaction with surgical result, % (yes/no/unsure) 0.02
Satisfied 66 (51 – 79) 84 (73 – 93)
Unsatisfied 4 (0 – 9) 7 (0 – 14)
Unsure 30 (19 – 43) 9 (0 – 18)
Data are mean (SD), mean (95% CI), median (lower and upper quartiles) or frequencies (95% CI). Data were analysed using the students t-test, Mann–Whitney
U-test or the χ2 test
Table 2 Data imputation of pain scores
Dexa VAS Back Placebo VAS Back P-value Dexa VAS Leg Placebo VAS Leg P-value
Responders only 22 (16–28) 20 (14–28) 0.47 26 (19–33) 17 (10–26) 0.03
Multiple imputation 22 (20–24) 20 (18–22) 0.20 24 (22–27) 17 (16–19) <0.001
Average imputation 22 (18–27) 20 (17–24) 0.53 25 (20–30) 17 (13–21) 0.03
Best case imputation 11 (7–16) 11 (7–16) 1.00 10 (5–15) 10 (5–15) 1.00
Worst case imputation 44 (36–53) 44 (37–51) 1.00 47 (38–56) 48 (39–56) 0.81
Data are mean (95% CI)
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It has been suggested that the potent immunomodula-
tory benefits of dexamethasone could possibly inhibit
the development of chronic pain [1, 21]. Few clinical tri-
als have investigated this effect of corticosteroids in
postoperative patients [4, 22–25]. Only one trial, testing
a bolus and 4 days of intravenous infusion of hydrocorti-
sone, found a significant positive impact on chronic pain
6 months postoperatively [24]. Despite a significant anal-
gesic effect of dexamethasone on acute pain during
mobilization 2–24 h postoperatively for both the total
study population and in the subgroup of 1-year follow-
up responders (post hoc analysis), we were not able to
demonstrate any inhibitory effects of dexamethasone on
chronic pain 1 year postoperatively.
In contrast we found increased pain levels in the dexa-
methasone group, specifically leg pain, indicating in-
creased levels of neuropathic pain. In our original trial,
16% (95% CI 7–26) versus 8% (95% CI 0–17) reported
new weakness and/or paralysis of the legs affecting the
ability to walk in the dexamethasone and placebo
groups, respectively, 3 months postoperatively (P = 0.20)
[17]. It is uncertain whether this result is related to our
findings of leg pain 1 year postoperatively, but we did
find a significantly higher number of patients in the
Fig. 3 Scatterplot of leg pain (VAS mm) 3- and 12 months postoperatively
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dexamethasone group with leg pain > 30 mm both 3-
and 12 months postoperatively.
Recent experimental trials in rats have demonstrated
that glucocorticoid receptors in the spinal cord are up-
regulated after constriction nerve injury, and imply that
glucocorticoids can worsen neuropathic pain behavior
[26–29]. These results imply an important function of
neuronal glucocorticoid receptors in the mechanisms of
neuropathic pain behaviors in rats and suggest a possible
role for glucocorticoid receptor antagonists in the treat-
ment of neuropathic pain. Other studies have found that
by inhibiting the release of prostaglandins, and produc-
tion of proinflammatory cytokines, excitatory amino
acids, and growth factors in animal models, glucocorti-
coids prevented the development of neuropathic pain be-
havior [9, 10]. Therefore, at present, results on the effect
of glucocorticoids after nerve injury are conflicting. Even
when adjusting for non-responders by data imputation we
found no preventive effect of dexamethasone on persistent
pain. When performing multiple- and average imputation
we found similar results to those of the responders with
higher levels of leg pain in the dexamethasone group.
When performing best case- and worst case imputations
we found no differences between groups.
Despite significantly higher pain levels in the dexa-
methasone group we did not find significant differences
in ability to work, length of sick leave, disability or self-
reported health between groups. However, for both the
dexamethasone and placebo groups, pain levels were low
in the Spine Unit Questionnaire and EQ-5D, and low to
moderate in the Oswestry Index Score for pain.
Table 3 SF-36, eight section scores
Dexamethasone Placebo P-value
Physical health
Physical function 75 (50 – 75) 75 (50 – 100) 0.10
Role physical 75 (0 – 100) 100 (50 – 100) 0.25
Bodily pain 76 (46 – 94) 82 (47 – 100) 0.12
General health 68 (43 – 80) 80 (55 – 93) 0.15
Mental health
Vitality 60 (40 – 80) 70 (50 – 80) 0.21
Social function 100 (72 – 100) 100 (50 – 100) 0.89
Role emotional 100 (50 – 100) 100 (50 – 100) 0.41
Mental health 70 (58 – 90) 80 (70 – 90) 0.22
Data are median with lower and upper quartiles. Data were analysed using the
Mann–Whitney U-test. Zero is equivalent to maximum disability and a score of
100 is equivalent to no disability
Fig. 4 EuroQol. Significant difference in severity of Pain/Discomfort with 28/67/5% in the dexamethasone group reporting no pain/moderate
pain/severe pain respectively and in the placebo group 50/45/5% reported no pain/moderate pain/severe pain respectively, P = 0.034
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Elevated blood glucose levels are a potential concern
of glucocorticoids, but the hyperglycemic responses
measured in current trials are modest at most. Several
large reviews have investigated this risk; and so far, there
is no solid evidence that a single dose of glucocorticoids
is associated with hyperglycemic responses affecting
postoperative morbidity [1, 2, 30, 31]. Based on this, we
did not measure blood glucose in our study.
A major limitation of this 12 months follow-up study
is the response rate of 65%, rendering data with low
strength to draw final conclusions on dexamethasone’s
role in preventing persistent postoperative pain. We do
not know the status of patients that did not respond. If
patients with high pain levels are more motivated to re-
spond this could potentially lead to a false positive result
(type 1 error). However, this should be similar in both
groups. We found no differences in patient characteris-
tics between responders and non-responders. Further
our imputations of missing data did not contribute with
new indications that dexamethasone can prevent persist-
ent postoperative pain. Our study contains exploratory
secondary outcomes from an original trial. Thus, the
sample size calculation was not performed with regards
to these secondary outcomes. Many of the questions in
the questionnaires regard the same topic and we would
therefore have to do multiple corrections introducing a
greater risk of ignoring a relationship that is real and
performing a type 2 error. As we consider these out-
comes hypothesis generating, we chose not to correct
for multiple comparisons and interpret the results with
respect to the increased risk of type 1 errors.
Further this study suffers from the well-known weak-
nesses of written questionnaires: Suboptimal response
rates, a level of subjectivity, recall bias, interpretation of
questions, and researcher imposition. The strength of
the study is that very few investigators were involved in
the trial, leading to few protocol violations, and very few
original data missing.
Future studies on possible effects and safety aspects of
dexamethasone on sustained postoperative pain are war-
ranted. We consider our results on back pain incidence
after lumbar back surgery as a significant negative find-
ing in this study. The exact dose of glucocorticoids at
which potential harm outweighs benefit is still unknown.
Conclusions
In conclusion, we found no inhibitory effect of dexa-
methasone on chronic pain 1 year after lumbar disc sur-
gery. In contrast we observed significantly higher pain
levels in the dexamethasone group compared to placebo,
which may be of concern. Our results may be considered
as hypothesis generating for future properly sized studies
investigating long-term effects of perioperative glucocor-
ticoids on human postoperative pain.
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